Spasticity vs. Rigidity: Key Distinctions
No, spasticity does not equal rigidity—these are fundamentally different motor abnormalities with distinct pathophysiology, clinical characteristics, and treatment approaches. In adults with multiple sclerosis, spasticity is the relevant motor disorder, not rigidity.
Pathophysiological Differences
Spasticity is a velocity-dependent increase in muscle tone caused by upper motor neuron lesions, characteristic of conditions like MS, stroke, and spinal cord injury. The resistance increases with faster passive movement and demonstrates a "clasp-knife" phenomenon where resistance suddenly releases 1, 2.
Rigidity, in contrast, is velocity-independent increased muscle tone seen in extrapyramidal disorders like Parkinson's disease, characterized by constant resistance throughout the range of motion regardless of movement speed (described as "lead-pipe" or "cogwheel" rigidity) 3, 4.
Clinical Presentation in Multiple Sclerosis
In MS patients, spasticity results from inflammatory demyelination affecting descending motor pathways in the central nervous system 5, 3. Common manifestations include:
- Velocity-dependent increased tone in anti-gravity muscles (flexors in upper extremities, extensors in lower extremities) 1, 2
- Painful muscle spasms that interfere with function, positioning, and rehabilitation 6, 7
- Impaired gait, bladder dysfunction, and difficulty with activities of daily living 5, 4
- Exacerbation with rapid passive stretching, resolving with slow movement 1
Treatment Implications
The distinction is critical because treatment strategies differ completely:
For Spasticity (MS patients):
- First-line: Non-pharmacological approaches including stretching, range of motion exercises, positioning, and splinting 1, 2
- Focal spasticity: Botulinum toxin injections are the preferred pharmacological intervention, with evidence showing effectiveness for both upper and lower extremity spasticity 6, 1, 7
- Generalized spasticity: Oral baclofen (30-80 mg/day divided into 3-4 doses), tizanidine, or dantrolene 1, 2
- Refractory cases: Intrathecal baclofen for severe spasticity unresponsive to oral medications 2
For Rigidity (Parkinsonian disorders):
- Dopaminergic medications (levodopa/carbidopa)
- Deep brain stimulation for refractory cases
- Antispasticity agents like baclofen and botulinum toxin are NOT effective for rigidity
Common Clinical Pitfall
A critical error is misidentifying spasticity as rigidity or vice versa, leading to inappropriate treatment. In MS patients presenting with increased muscle tone:
- Always assess velocity-dependence during passive movement 1
- Look for the clasp-knife phenomenon characteristic of spasticity 2
- Evaluate for other MS symptoms (optic neuritis, sensory disturbances, Lhermitte sign, bladder dysfunction) rather than parkinsonian features (bradykinesia, resting tremor, postural instability) 5, 3, 4
MS causes spasticity, not rigidity—treating with appropriate antispasticity interventions rather than antiparkinsonian medications is essential for optimal outcomes 6, 1, 2.